Immunomodulatory drugs for multiple sclerosis: A systematic review of clinical and cost effectiveness

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 4, 2001, Pages 623-639

  Clegg, A ^a   Bryant, J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Azathioprine; Cladribine; Clinical effectiveness; Cost effectiveness; Cyclophosphamide; Economic evaluation; Glatiramer; IFN ; Immunomodulatory drugs; Intravenous immunoglobulin; Methotrexate; Mitoxantrone; Multiple sclerosis; Systematic review

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; PLACEBO; BETA INTERFERON; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADVERSE DRUG REACTION; ALOPECIA; AMENORRHEA; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISABILITY; DISEASE COURSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ECONOMIC EVALUATION; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INJECTION SITE; MEDICAL EXPERT; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; URTICARIA; COST BENEFIT ANALYSIS; ECONOMICS;

AZATHIOPRINE; CLADRIBINE; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DRUG COSTS; HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; METHOTREXATE; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES; SUPPORT, NON-U.S. GOV'T;

EID: 0035003031     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.4.623     Document Type: Review

References (50)

1. Drug therapy in multiple sclerosis
2. Drug treatment of multiple sclerosis
3. Ruling on interferon beta will hit all health authorities
4. Interferon beta in multiple sclerosis
5. Disease modifying drugs for multiple sclerosis: A rapid and systematic review
6. Assessing the quality of reports of randomised clinical trials: Is blinding necessary?
7. Users' Guides to the Medical Literature VII. How to use a clinical decision analysis A. Are the results of the study valid
8. Overview of azathioprine treatment in multiple sclerosis
9. A double blind study on azathioprine efficacy in multiple sclerosis: Final report
10. Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation
11. Randomised double-blind placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis
12. A Phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients
13. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
14. Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS Study
15. Comparison of drug treatments for multiple sclerosis
16. Beta Interferons (1a and 1b) in relapsing-remitting and secondary multiple sclerosis
17. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentre, randomised, double-blind, placebo-controlled trial
18. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
19. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
20. Population based cost-utility study of interferon beta-1b in secondary progressive multiple sclerosis
21. Cost-utility of interferon beta-1b in secondary progressive multiple sclerosis
22. A cost-utility analysis of interferon beta for multiple sclerosis
23. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression
24. Cladribine in treatment of chronic progressive multiple sclerosis
25. The treatment of chronic progressive multiple sclerosis with cladribine
26. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
27. Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial
28. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis
29. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH
30. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
31. Intense immunosuppression in chronic progressive multiple sclerosis: The Kaiser study
32. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
33. Copolymer 1 in relapsing-remitting multiple sclerosis
34. Neuropsychologic status in multiple sclerosis after treatment with glatiramer
35. Meta analysis of clinical trials with Copolymer 1 in multiple sclerosis
36. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double- blind, placebo-controlled trial
37. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
38. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
39. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
40. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
41. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
42. Low dose oral methotrexate treatment of multiple sclerosis: A pilot study
43. Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome
44. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
45. The hazards of scoring the quality of clinical trials for meta-analysis
46. The role of MRI in clinical trials of multiple sclerosis: Comparison of imaging process technique
47. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis; a meta-analysis
48. Costs, quality of life and disease severity in multiple sclerosis: A population-based cross sectional study in Sweden